The company presented data demonstrating that ADHD patients with mutations in nine genes had a clinically meaningful and statistically significant response to AEVI-001.
NEW YORK (GenomeWeb) – Neuropsychiatric molecular diagnostics firm Assurex today said that it has secured a $25 million credit facility and $7 million in investments.
The funds will be used to increase clinical adoption of the Mason, Ohio-based firm's GeneSight products.
NEW YORK (GenomeWeb News) – The European Union has approved a project aimed at determining the causes of extreme aggressive behavior and is providing €6 million ($8 million) to the effort.
AssureRx Launches GeneSightRx ADHD
AssureRx Health this week launched a pharmacogenetic test, called GeneSightRx ADHD, for characterizing patients' response to a variety of attention deficit hyperactivity disorder drugs.
